830346-48-0Relevant articles and documents
AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS
-
, (2021/07/02)
The present invention relates to an improved process for the preparation of 4- ({(1R) -2- [5- (2-fluoro- 3- methoxy phenyl) – 3 - {[ 2-fluoro- 6-(trifluoro methyl) phenyl] methyl} -4-methyl- 2,6-dioxo- 3,6-dihydropyrimidin-1(2H)-yl]-1-phenylethyl}amino) butanoic acid of formula (I) or its pharmaceutically acceptable salts. The compound of formula (I) is represented by the following structural formula.
Preparation method of oxlagrel intermediate
-
Paragraph 0055-0064, (2020/12/10)
The invention relates to a preparation method of an oxlagrel intermediate. The preparation method comprises the following steps: dissolving a 2-fluoro-6-(trifluoromethyl)benzyl bromide compound 7 in an aprotic polar solvent, then adding alkali carbonate and urea, carrying out a heating reaction under stirring, and after the reaction is finished, carrying out post-treatment and recrystallization toobtain a compound 4, the yield being 89-95 wt%; and dissolving the compound 4 prepared in the step (1) into the aprotic polar solvent; then, adding a 2-bromoacetoacetic acid ethyl ester compound 9, and cooling to 3 DEG C or below, adding bromo-organosilane while stirring, then continuing to stir and react at 80 DEG C or below, and after the reaction is finished, carrying out aftertreatment and recrystallization to obtain the target product 5-bromo-1-(2-fluoro-6-trifluoromethylbenzyl)-6-methylpyrimidine (1H, 3H)-2,4-diketone compound 1, the yield being 75-88 wt%. The method is simple in synthetic route and simple and convenient in post-treatment mode.
PROCESS FOR THE PREPARATION OF ELAGOLIX AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
-
Page/Page column 12; 13, (2018/11/22)
The present invention relates to a process for the preparation of Elagolix of formula (I) and its pharmaceutically acceptable salts. The present invention also relates to an intermediate of formula (VIII) and its use in preparation of Elagolix and its pharmaceutically acceptable salts.